Table 1.

Contributing speakers and highlights of their talks.

Speaker	Affiliation	Title of Talk	Highlights
Prof. David Finlay	Trinity College, Dublin, Ireland	Fuelling robust anti-tumour natural killer (NK) cell responses	Metabolic drugs might synergistically enhance immunotherapy via metabolic reprogramming of the tumour microenvironment (TME).
Prof. Peter Jones	Van Andel Institute, Grand Rapids, Michigan, U.S.	Epigenetic therapies	Epigenetic treatments are already incorporated into clinical practice for blood-related malignancies and are actively investigated in combination with conventional therapies in solid tumours. Further understanding of their mechanisms also reveals a possible link with enhancing patients’ immune response.
Dr. Noel McCaffrey	Dublin City University, Ireland	Community-based exercise in cancer survivorship	While physical exercise is not currently being used in specific combination therapies, it is emerging as a very promising intervention for cancer management and will undoubtedly gain centre stage in the future as a novel approach to target cancer cells.
Dr. Gillian Prue	Queen’s University, Belfast, Northern Ireland	When exercise is the drug: can activity levels really be used to treat prostate cancer?
Dr. Sara Charmsaz	Royal College of Surgeons in Ireland, Ireland	RNA-methylation in Estrogen Receptor (ER)-positive breast cancer	The development of ‘omics’ technologies will allow us to better predict the response to combination therapies, thus improving our ability to use them in the clinic.